Peptides Similar to Dermorphin

Peptides Related to Dermorphin#

Dermorphin belongs to a broader class of opioid peptides that interact with opioid receptors in the nervous system. Several peptides share functional or structural overlap with dermorphin, though each has distinct pharmacological properties. Below is a comparison of key related compounds.

Deltorphin (Delta-Opioid Selective Frog Peptide)#

Deltorphin (also known as deltorphin I and II) is another opioid peptide isolated from the skin of Phyllomedusa frogs, sharing its biological origin with dermorphin. Like dermorphin, deltorphins contain a D-amino acid at position 2 (D-Ala or D-Met), but their C-terminal "address" domains confer selectivity for delta-opioid receptors rather than mu-opioid receptors. Deltorphin II (Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2) is among the most selective delta-opioid agonists known.

The co-occurrence of mu-selective (dermorphin) and delta-selective (deltorphin) opioid peptides in the same frog species has provided researchers with a natural set of complementary pharmacological tools. Together, these peptides have been instrumental in dissecting the distinct roles of mu and delta opioid receptor subtypes in analgesia, reward, and other physiological processes.

DAMGO (Synthetic Mu-Opioid Agonist)#

[D-Ala2, N-MePhe4, Gly-ol5]-enkephalin (DAMGO) is a synthetic peptide that, like dermorphin, is highly selective for the mu-opioid receptor. DAMGO was designed through systematic modification of the enkephalin sequence and has become the standard reference mu-agonist in pharmacological research. While dermorphin and DAMGO share comparable mu-receptor selectivity, their structural scaffolds are different: DAMGO is a pentapeptide enkephalin derivative, whereas dermorphin is a heptapeptide with a distinct sequence.

Both peptides produce potent, naloxone-reversible analgesia in animal models. DAMGO has been more widely used as a reference standard in receptor binding assays, while dermorphin has unique value as a naturally occurring mu-selective agonist. The comparison of these two peptides has helped elucidate structure-activity relationships at the mu-opioid receptor.

Endomorphin-1 and Endomorphin-2#

The endomorphins (endomorphin-1: Tyr-Pro-Trp-Phe-NH2; endomorphin-2: Tyr-Pro-Phe-Phe-NH2) are endogenous mammalian peptides proposed as the natural ligands for mu-opioid receptors. Unlike dermorphin, endomorphins contain exclusively L-amino acids, which renders them more susceptible to enzymatic degradation. Both endomorphins demonstrate high mu-receptor selectivity but generally lower potency than dermorphin in direct comparison assays.

The discovery of endomorphins in the 1990s provided a mammalian counterpart to the frog-derived dermorphin and raised questions about the evolutionary conservation of mu-receptor selective peptide ligands. While dermorphin remains a more potent pharmacological tool, endomorphins offer insights into the endogenous regulation of mu-opioid receptor signaling.

Beta-Endorphin#

Beta-endorphin is a 31-amino-acid endogenous opioid peptide produced by the anterior pituitary gland. Unlike dermorphin, beta-endorphin is not highly selective for any single opioid receptor subtype, binding to both mu and delta receptors with similar affinity. Beta-endorphin has a much longer sequence and higher molecular weight than dermorphin, and its pharmacological profile reflects a broader range of opioid receptor interactions.

Dermorphin's advantages over beta-endorphin as a research tool include its greater mu-selectivity, smaller size, and enhanced metabolic stability due to the D-amino acid residue.

Morphine and Synthetic Opioids#

While morphine is an alkaloid rather than a peptide, comparing it with dermorphin provides important context. Dermorphin demonstrates 30- to 40-fold higher affinity for mu-opioid receptors compared to morphine, and up to 670-fold greater analgesic potency in certain bioassays. However, morphine has the advantage of oral bioavailability and well-characterized clinical pharmacology spanning over a century of medical use, whereas dermorphin remains a research compound with no approved clinical applications.

Comparative Summary#

Combination Research#

Limited preclinical research has examined the combined effects of dermorphin with delta-opioid agonists such as deltorphin. Synergistic analgesic effects between mu and delta agonists have been reported, suggesting potential for combination approaches that could achieve analgesia at lower individual doses. However, this remains an area of active investigation with no translational studies to date.

Related Reading#

• Dermorphin overview and research guide
• Dermorphin research evidence
• Dermorphin dosing protocols